NICE’s Eylea guideline ‘out of touch with clinical practice’
Bayer says it is disappointed that the National Institute for Health and Care Excellence is supporting NHS use of anti-VEGF therapy Eylea to treat a common cause of visual impairment only in the second-line setting.
Read More
